<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334694</url>
  </required_header>
  <id_info>
    <org_study_id>01/2020/W</org_study_id>
    <nct_id>NCT04334694</nct_id>
  </id_info>
  <brief_title>Atrial Flow Regulator in Heart Failure</brief_title>
  <acronym>PROLONGER</acronym>
  <official_title>Pomeranian atRial flOw reguLatOr iN conGestive hEart failuRe (PROLONGER) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Szpitale Pomorskie Sp. z o. o.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Szpitale Pomorskie Sp. z o. o.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess invasive and non-invasive parameters that may predict
      clinical improvement in patients with congestive heart failure after implantation of
      Occlutech® Atrial flow regulator (AFR) device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All eligible patients will undergo detailed screening using echocardiography, impedance cardiography and right heart catheterization prior to AFR implantation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in 6 minutes walk test distance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement II</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction in New York Heart Association (NYHA) class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>Device migration, embolization, device related thrombus, shunt occlusion, need for device removal</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulmonary artery wedge pressure (PAWP) at rest</measure>
    <time_frame>30 days after AFR</time_frame>
    <description>Reduction of PAWP at rest</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary artery wedge pressure (PAWP) during handgrip test</measure>
    <time_frame>30 days after AFR</time_frame>
    <description>Reduction of PAWP during handgrip test</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ-12</measure>
    <time_frame>12 months</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ-12)</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical adverse event II</measure>
    <time_frame>12 months</time_frame>
    <description>Rehospitalization for HF decompensation</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Atrial flow regulator</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm, patients who have elevated left ventricle filling pressures get (Occlutech® AFR device) and optimal therapy for Heart failure (HF).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atrial flow regulator (Occlutech® AFR device)</intervention_name>
    <description>Atrial septostomy followed by implantation of AFR.</description>
    <arm_group_label>Atrial flow regulator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Symptomatic heart failure (HF) in NYHA class III or IV ambulatory

          -  Optimal medical therapy of HF according to European Society of Cardiology (ESC)
             guidelines for last 6 months

          -  Hospitalization because of HF decompensation in last 12 months

          -  Absence of significant valvular disease requiring cardiac surgery

          -  Life expectancy ≥ 1 year

          -  Written informed consent obtained from the patient

          -  Left ventricle ejection fraction (LVEF) ≥ 15%

          -  Elevated left heart filling pressures:

               1. Pulmonary artery wedge pressure (PAWP) at rest &gt; 15 mmHg or

               2. PAWP &gt; 25 mmHg during hand grip test

        Exclusion Criteria:

          -  Participation in another clinical trial in last 30 days

          -  Acute infection or sepsis

          -  Severe coagulation disorder

          -  Allergy to nickel or titanium

          -  Severe peripheral artery disease disabling 6 minutes walk test

          -  Allergy to antiplatelet drugs, oral anticoagulants or heparin

          -  Contraindication to trans-oesophageal echocardiography (TEE)

          -  Pregnancy

          -  Atrial septal defect (ASD) or presence of atrial septal occluder

          -  Severe patent foramen ovale (PFO) with significant left to right shunt in rest

          -  Intracardiac thrombus

          -  Acute coronary syndrome or Percutaneous Coronary Intervention (PCI) or Coronary Artery
             Bypass Grafting (CABG) in last 6 months

          -  Severe pulmonary hypertension:

               1. Right atrial pressure ≥ PAWP (measured in right heart catheterization)

               2. Right atrial pressure &gt; 20 mmHg (measured in right heart catheterization)

          -  Planned heart transplantation

          -  Transient ischemic attack or stroke within last 6 months

          -  Cardiac resynchronisation therapy (CRT) within last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukasz Lewicki, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kashubian Cardiovascular Center; University Center for Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukasz Lewicki, MD, PhD</last_name>
    <phone>+48501702885</phone>
    <email>luklewicki@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maciej Karwowski, MD</last_name>
    <phone>+48500473983</phone>
    <email>maciejkarwowskimd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kashubian Cardiovascular Center</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukasz Lewicki, MD,PhD</last_name>
      <phone>+48501702885</phone>
      <email>luklewicki@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maciej Karwowski, MD</last_name>
      <phone>+48500473983</phone>
      <email>maciejkarwowskimd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lukasz Lewicki, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maciej Karwowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Liedtke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarzyna Kosmalska, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marek Szolkiewicz, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial flow regulator; heart failure; interatrial shunting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The following data will be available:
echocardiography reports
right heart catheterization reports
clinical and demographic data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The data will be available after completion of the study.</ipd_time_frame>
    <ipd_access_criteria>The data will be shared on personal request for review process.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

